Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Its use outside of formally approved clinical trials is not sanctioned
Lancet 403 (10437), 16351648 (2024)
Regular follow-ups focused on optimizing her medication regimen, dietary counseling to manage side effects and enhance the effectiveness of her treatments, and education on the importance of medication adherence
Key Summary: In addition to meeting the primary objective of noninferiority to semaglutide in type 2 diabetes (T2D), tirzepatide, at a dose of either 10 mg or 15 mg once weekly, has demonstrated superiority to semaglutide in this indication
Maximum of 1 per order
Tirzepatide (Mounjaro/Zepbound) may cause slightly more GI side effects overall because it targets two receptors (GLP-1 + GIP), but individual responses vary
US$ 25.55
US$ 23.18
US$ 21.13
